Fig. 6: High DILA1 expression is associated with higher Cyclin D1 protein expression, tamoxifen resistance, and poor prognosis in ER-positive breast cancer patients.
From: LncRNA DILA1 inhibits Cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer
a ISH staining for DILA1 and IHC staining for Cyclin D1, p-D1(Thr286), p-Rb(Ser780), and Ki67 in breast cancer specimen from ER-positive patients with or without relapse. Representative images of tumor specimens from ER-positive patients with (n = 36) or without relapse (n = 154) are shown. Scale bars, 50 μm. b–e The distribution of Cyclin D1, p-D1(Thr286), p-Rb(Ser780), and Ki67 determined by the staining index in the high (n = 109) or low (n = 81) DILA1-expressing groups. n = 190, p values were determined by two-tailed Chi-square test. f, g The distribution of DILA1 (f) and Cyclin D1 (g) by the staining index in the samples of ER-positive patients with (n = 36) or without relapse (n = 154). n = 190, means ± s.d. are shown, p values were determined by two-tailed Student’s test. h, i Relapse-free survival of ER-positive breast cancer patients with low and high DILA1 (h) or Cyclin D1 (i) was analyzed by Kaplan–Meier plots. n = 190, p values were determined by two-tailed log-rank test.
